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Abstract The main objective of the present study is to
evaluate the misalignment between psoriatic arthritis (PsA)
patient- and physician-reported satisfaction with PsA control.
Data came from the Adelphi Rheumatology Disease Specific
Programme, a retrospective, cross-sectional survey of US-
based rheumatologists and patients. Physicians provided satis-
faction and clinical characteristics on tender joint count, swol-
len joint count, and percent body surface area (BSA) affected
by psoriasis. Patients provided data on satisfaction, the Work
Productivity Activity Impairment and Health Assessment
Questionnaire-Disability Index (HAQ-DI) questionnaires.
Based on their satisfaction response, patient-physician pairs
were classified into aligned (both satisfied or dissatisfied) or
misaligned (rated satisfaction differently) groups. Multivariate
analysis evaluated association of characteristics with misalign-
ment. Among 305 paired patient-physician records analyzed,
23.6% were misaligned and 76.4% were aligned. The
misaligned group had shorter disease duration (mean years,
5.2 vs. 6.4), used fewer biologic disease-modifying antirheu-
matic drugs (49.3 vs. 62.9%), had more swollen (mean, 3.7 vs.
1.9, P = 0.0002) and tender joints (mean, 5.6 vs. 2.9,
P < 0.0001), greater proportion of patients with comorbidities
(72.2 vs. 63.1%), and >3% BSA affected by psoriatic skin
lesions (64.2 vs. 55.1%). Misaligned patients reported greater
work impairment (mean, 38.7 vs. 21.4, P = 0.0004), daily
activities (mean, 38.7 vs. 22.3, P < 0.0001), and higher disease
burden (mean HAQ-DI; 0.56 vs. 0.37, P = 0.0001).
Multivariate analysis found the number of swollen joints
(P = 0.02) and HAQ-DI score (P = 0.03) was significantly
associated with misalignment among all patients; however,
not in the subgroup of employed patients. Patient-physician
misalignment is associated with increased disease activity and
disability among patients with PsA.
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Introduction
Psoriatic arthritis (PsA) is a common chronic, disabling,
immune-mediated disease, affecting the peripheral and axial
joints, nails, and entheses, and is often associated with psori-
atic skin lesions [1, 2]. Patients with PsA experience inflam-
mation, pain, and swelling of the joints, in addition to the
scaling, itching, and skin pain associated with psoriasis [3].
In the USA, the prevalence of PsA ranges from 0.10 to 0.25%,
with approximately 30% of patients with psoriasis developing
PsA [2, 4]. Current treatments for PsA focus on reducing
inflammation and pain [3, 5, 6]. Treatment of PsA typically
involves non-steroid anti-inflammatory drugs, intra-articular
corticosteroid injections for mild disease, non-biologic dis-
ease-modifying antirheumatic drugs (nbDMARDs), biologics
DMARDs (bDMARDs), and a recent classification of
targeted synthetic DMARDs (tsDMARDs) [3, 5–10].
The assessment of disease activity in PsA relies partially on
patient-reported outcomes in combination with clinical and
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laboratory evaluation by the physician [11, 12]. Alignment
between physicians and patients with respect to PsA activity
is important for the optimal implementation of a treatment
plan and to promote the most effective outcome for patients
[13–17]. The Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis suggests that the assessment of PsA
activity should include the simultaneous evaluation of arthri-
tis, axial disease, enthesitis, dactylitis, patient and physician
global assessment, physical function, health-related quality of
life, and skin and nail disease [13–17].
Although validated physician-reported instruments for de-
termining disease activity in PsA have allowed better disease
assessment, a number of challenges still exist [18]. PsA symp-
toms are heterogeneous, and the global disease burden is usu-
ally a composite of the different symptoms. In addition, cer-
tain symptoms may have a greater influence on the perception
of PsA activity, which may differ between the patient and
physician [18]. A patient’s point of view is typically based
on their experience with PsA over a long period of time, while
a physician’s perception of PsA activity is related to his or her
professional experience [18].
A limited number of studies have evaluated misalignment
between patients and physicians with regard to PsA activity.
Findings from these studies suggest a significant disconnec-
tion in the manner in which PsA patients and their rheumato-
logists define and report PsA activity and control [11, 18, 19].
Currently available data also indicate low patient satisfaction
with care among some patients with PsA and has been
associated with a lack of psychological support and know-
ledge about PsA and treatment [20]. Hence, the aim of this
study was to ascertain the extent of misalignment between
patient- and physician-reported satisfaction with PsA control
and its association with PsA activity and disease burden. In
patients who had active joint disease, an exploratory analysis
was undertaken to describe and compare the characteristics of




This analysis used data retrieved from the Adelphi Disease
Specific Programme, a large, syndicated, retrospective, multi-
national surveys of physicians and patients in a real-world
clinical setting for a range of common diseases [21]. The
Disease Specific Programme collects quantitative and qualita-
tive survey data and provides a comprehensive overview of a
given disease and treatment of that disease from the perspec-
tive of both physician and patient [21]. Two Rheumatology
Disease Specific Programme surveys conducted in the USA
between January and March 2011 and over a similar time
period in 2014, were used for this study. The Disease
Specific Programme included a geographically diverse sample
of US rheumatologists and their respective patients with PsA.
The Rheumatology Disease Specific Programme was con-
ducted in accordance with the US Health Insurance
Portability and Accountability Act 1996 (HIPAA; www.hhs.
gov/ocr/privacy/) and the Health Information Technology for
Economic and Clinical Health legislation (2014 only as this
legislation was not present in 2011). The Disease Specific
Programme is a market research project and complies with
all relevant market research guidelines and legal obligations.
The research methodology and nature of the collected data
make submission to national and/or local ethics committees
and regulatory bodies unnecessary. Namely, the Disease
Specific Programme is non-interventional and employs solely
a retrospective data collection, and both physician and patient
data are collected anonymously and independently.
Physicians were identified from public lists of healthcare
professions. The physician sample included 200 US rheuma-
tologists (100 sampled in each year) responsible for managing
patients with PsA. Eligible physicians had to meet the follow-
ing pre-specified criteria: primary specialty was rheumatolo-
gy, currently treating rheumatoid arthritis (RA), PsA, and
spondyloarthropathy; typical monthly workload involved
consultations with three or more patients with PsA; and qual-
ification as a physician between 3 and 40 years prior to initi-
ation of the survey.
Each physician completed a response form for three con-
secutive, consulting, adult patients with PsA, generating 600
forms across the two surveys. Eligible patients had to be
≥18 years of age and have a diagnosis of PsA on or before
the day of consultation. Patients were excluded if they were
involved in a clinical trial. All patients gave their informed
consent. Subjects had the right to opt-out of the survey at
any time.
Survey design
The Rheumatology Disease Specific Programme was deve-
loped by Adelphi Real World (Adelphi Real World, Cheshire,
UK). All physician-completed patient record form answers
were confidential and maintained physician and patient ano-
nymity; data were fully de-identified prior to receipt by the
research team. The physician-completed patient record form
provided information on a wide a range of patient and disease
characteristics, including demographics, comorbidities, symp-
tomatology, and satisfaction with PsA control. All data from
the physician-completed patient record form were based on ev-
idence available to the physician at the time of the consultation;
no tests or investigationswere performed as part of this research.
Patients were asked to fill out patient self-completed ques-
tionnaires on a voluntary basis. To preserve anonymity, pa-
tients were asked to complete the form independently of the
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physician and return the patient self-completed questionnaires
in a sealed envelope. To ensure the physician did not see any
patient responses (including patient-reported outcome mea-
sures and symptom assessments), the patient put their re-
sponses in an envelope and sealed this prior to return. Each
pair of forms (i.e., the physician-completed patient record
form and the patient self-completed questionnaire) was linked
during data processing using non-identifying unique identifi-
cation numbers. All eligible pairs of linked physician-
completed patient report forms and the patient self-completed
questionnaires were included for analysis.
Patients reported their satisfaction with PsA control; in
2011, this was in response to a categorical question, and
in 2014, this was captured as a response to a Likert scale
(Fig. 1).
The validated Work Productivity Activity Impairment
(WPAI) [20] and Health Assessment Questionnaire-Disability
Index (HAQ-DI) (HAQ-DI max = 3.0) [21] questionnaires
were included in the patient self-completed questionnaires for
completion by patients, allowing scores to be derived for both
measures. The overall percentage of Bwork impairment^ as
well as the percentage of Bpresenteeism^ and Babsenteeism^
was calculated for patients who were employed at the time of
the survey. However, the percentage of Bactivity impairment^
derived from the WPAI responses was calculated for the whole
sample (both employed and unemployed patients).
Determination of misalignment on satisfaction
The responses to the satisfaction questions from each pair of
linked forms (physician-completed patient record form and pa-
tient self-completed questionnaire) were compared to deter-
mine if the physician and patient pair were ‘aligned’ or
‘misaligned’ in terms of their satisfaction with PsA control.
Pairs were classified as ‘aligned’ when both the patient and
physician felt satisfaction or dissatisfaction in terms of PsA
control or as ‘misaligned’ when the physician felt satisfied,
but the patient was dissatisfied with PsA control or vice versa.
Variables
Study variables of interest included physician and patient
reported satisfaction with PsA control, demographics charac-
teristics, disease characteristics, and burden of disease. The
following variables were captured from physicians in the
physician-completed patient record form: satisfaction with
PsA control (categorized as satisfied or dissatisfied), patient
age, sex, comorbidities (listed below), time since diagnosis
measured in years, current treatment (e.g., topical agents,
nbDMARDs, bDMARDs), tender joint count (TJC), swollen
joint count (SJC), percent body surface area (BSA) affected by
psoriatic skin lesions, and number of PsA symptoms currently
present including joint symptoms (tenderness, swelling,
Fig. 1 Determination of whether physicians and patients were satisfied or dissatisfied with control. (Note: Physicians and patients responded to specific
questions, and depending upon their response were considered satisfied or dissatisfied with PsA control; PsA psoriatic arthritis)
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stiffness, etc.) and skin symptoms for those with psoriatic skin
lesions (itching, pain, scaling, etc.). Comorbidities included
anxiety, depression, type 2 diabetes, hyperlipidemia/elevated
cholesterol, gastric condition, hypertension, liver impairment,
malignancy, obesity, renal impairment, osteoporosis, respira-
tory conditions, tuberculosis, and vasculitis. The patient self-
completed questionnaire captured satisfaction with PsA
control (categorized as satisfied or dissatisfied), WPAI (a per-
centage of overall work impairment scored as 0 to 100%
impairment and impairment of Bpresenteeism^, Babsenteeism^,
and activity impairment) [20], and HAQ-DI (continuous vari-
ables of scores ranging from 0 to 3 with a score of 0 indicating
performance without any difficulty and up to score 3 meaning
performance cannot be done at all) [21].
Data analysis
Data were reported descriptively for each variable (i.e.,
patient age, sex, comorbidities, time since diagnosis, cur-
rent treatment, TJC, SJC, percent BSA affected by psoria-
tic skin lesions, number of PsA symptoms currently pre-
sent, HAQ-DI scores, and WPAI responses). Categorical
variables were summarized using frequency counts and
percentages. Continuous variables were summarized by
the number of observations, their mean, and standard
deviation (SD).
Bivariate statistical comparisons were made between the
aligned and misaligned groups for each variable. P values
were obtained using the Wilcoxon rank-sum test for con-
tinuous variables, and Fisher’s exact test for categorical
variables.
For the primary objective, multivariate logistic regression
analyses evaluated what factors may be associated with pa-
tient and physician misalignment. Two analyses were per-
formed as follows: the first included all patient-physician
pairs and the second included the subgroup of patients who
were employed and had completed the WPAI. The depen-
dent variable was whether patients were aligned with their
physicians in regard to satisfaction of PsA control.
Independent variables included age, current bDMARD treat-
ment, SJC, percent BSA affected by psoriatic skin lesions,
and HAQ-DI. For the multivariate analysis, TJC was omitted
from the model because there was multicollinearity with
SJC. In addition, TJC is confounded by other diseases, such
as osteoarthritis, and is an indirect measure of inflammation
[22]. SJC, on the other hand, is a good measure of inflam-
mation [23]. All variables were included in the models at the
same time. Standard errors were adjusted to allow for possi-
ble intragroup correlation within the reporting physician. The
multivariate logistic regression was repeated on the subpop-
ulation of patients who had completed the WPAI using
WPAI as an independent variable to identify independent
predictors of misalignment of employed patients.
Sub-analysis of satisfaction with PsA control in patients
with active joint disease
An exploratory analysis was performed in two groups of pa-
tients with active joint disease (>3 TJC): satisfied and not sat-
isfied with PsA control. Data were reported descriptively for
each variable. Categorical variables were summarized using
frequency counts and percentages. Continuous variables were
summarized by the number of observations, the mean, and SD.
Bivariate statistical comparisons were made between the
satisfied and not satisfied groups for each variable. P values
were obtained using the Wilcoxon rank-sum test for continu-
ous variables, and Fisher’s exact test for categorical variables.
Results
Survey physician and patient population
A total of 327 patients completed a patient self-completed
questionnaire and were included in the analysis. Patients were
matched with their respective rheumatologist, who completed a
physician-completed patient record form. Twenty-two records
were excluded due to missing data relating to satisfaction from
either the patient or the physician. Therefore, 305 paired
rheumatologists and PsA patient records were eligible for
inclusion in the analysis.
Of the complete set of patient-physician records, 76.4%
were Baligned^, with 65.2% in the aligned group being both
satisfied and 11.1% being both dissatisfied with PsA control
(Table 1). The remaining 23.6% of patient-physician records
were Bmisaligned^. In the misaligned group, 17.0% of the
paired patient-physician records consisted of a satisfied patient
and dissatisfied physician, and 6.6% consisted of a dissatisfied
patient and satisfied physician.
Baseline demographics and disease characteristics
Themisaligned group had greater disease activity comparedwith
that of the aligned group. The aligned and misaligned groups
were similar with regard to age and gender (Table 2). In the
misaligned group, patients had a shorter disease duration (mean
years [SD] 5.2 [5.3] vs. 6.4 [7.1]) and a greater percentage were
not using bDMARD therapy (50.7 vs. 37.1%) compared with
those of the aligned group. Patients in the misaligned group also
tended to have more active disease than those of the aligned
Table 1 Paired patient-physician survey responses
Aligned patient-physician records, pairs, n (%) 233 (76.4)
Patient and physician both satisfied 199 (65.2)
Patient and physician both dissatisfied 34 (11.1)
Misaligned patient-physician records, pairs, n (%) 72 (23.6)
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group, with a significantly higher number of swollen (mean
[SD], 3.7 [4.0] vs. 1.9 [3.1], P = 0.0002) and tender joints (mean
[SD], 5.6 [5.5] vs. 2.9 [3.7], P < 0.0001) and a greater percentage
of patients had >3% of their BSA affected by psoriatic skin
lesions (64.2 vs. 55.1%). The misaligned group also had a
significantly greater number of PsA symptoms present (mean
[SD], 6.8 [3.8] vs. 4.9 [3.6], P = 0.0004) as well as a larger
percentage of patients with >5 symptoms (65.3 vs. 40.8%,
P = 0.0004) compared with those of the aligned group. The most
common comorbidities across both groups were hypertension
Table 2 Baseline demographics and disease characteristics
Overall, N = 305 Aligned, n = 233 Misaligned, n = 72 P valuea
Age (y), mean (SD) 50.0 (13.4) 50.0 (13.5) 49.8 (13.1) 0.99
Male, n (%) 168 (55.1) 129 (55.4) 39 (54.2) 0.89
Time since diagnosis (y), mean (SD) 6.1 (6.7) 6.4 (7.1) 5.2 (5.3) 0.28
Current bDMARD treatment, n (%)
None 122 (40.3) 86 (37.1) 36 (50.7) 0.05
Currently receiving bDMARD treatment 181 (59.7) 146 (62.9) 35 (49.3)
SJC, mean (SD) 2.4 (3.4) 1.9 (3.1) 3.7 (4.0) 0.0002
TJC, mean (SD) 3.5 (4.4) 2.9 (3.7) 5.6 (5.5) <0.0001
BSA affected, n (%)
≤3% 121 (42.8) 97 (44.9) 24 (35.8) 0.21
>3% 162 (57.2) 119 (55.1) 43 (64.2)
Number of PsA symptoms, mean (SD)b 5.4 (3.8) 4.9 (3.6) 6.8 (3.8) 0.0004
Number of PsA symptoms, n (%)b
≤5 163 (53.4) 138 (59.2) 25 (34.7) 0.0004
>5 142 (46.6) 95 (40.8) 47 (65.3)
Comorbidities
Number of comorbidities per patient, mean (SD) 1.2 (1.3) 1.1 (1.3) 1.4 (1.4) 0.11
Frequency of comorbidities (≥1), n (%) 199 (65.2) 147 (63.1) 52 (72.2) 0.20
Comorbidities, n (%)
Hypertension 88 (28.9) 67 (28.8) 21 (29.2) >0.9999
Hyperlipidemia/elevated cholesterol 61 (20.0) 49 (21.0) 12 (16.7) 0.50
Depression 43 (14.1) 28 (12.0) 15 (20.8) 0.08
Obesity 42 (13.8) 30 (12.9) 12 (16.7) 0.44
Anxiety 33 (10.8) 22 (9.4) 11 (15.3) 0.19
Gastric condition 31 (10.2) 22 (9.4) 9 (12.5) 0.50
Type 2 diabetes 28 (9.2) 18 (7.7) 10 (13.9) 0.16
Liver impairment 8 (2.6) 5 (2.1) 3 (4.2) 0.40
Malignancy 7 (2.3) 6 (2.6) 1 (1.4) >0.9999
Respiratory condition 7 (2.3) 5 (2.1) 2 (2.8) 0.67
Osteoporosis 6 (2.0) 4 (1.7) 2 (2.8) 0.63
Renal impairment 5 (1.6) 4 (1.7) 1 (1.4) >0.9999
Tuberculosis 2 (0.7) 2 (0.9) 0 (0) >0.9999
WPAI due to PsA, mean (SD)
Percentage of work-time missed 6.3 (17.3) 6.3 (17.0) 6.4 (18.3) 0.91
Percentage of impairment while working 20.7 (23.4) 16.5 (21.2) 36.2 (25.3) <0.0001
Overall percentage of work impairment 25.6 (27.9) 21.4 (26.7) 38.7 (27.9) 0.0004
Percentage of activity impairment 26.0 (25.0) 22.3 (24.0) 38.7 (24.5) <0.0001
HAQ-DI, mean (SD) 0.42 (0.48) 0.37 (0.48) 0.56 (0.43) 0.0001
bDMARD biologic disease-modifying antirheumatic drug, BSA body surface area, HAQ-DI health assessment questionnaire disability index, PsA
psoriatic arthritis, S standard deviation, SJC swollen joint count, TJC tender joint count, WPAI work productivity and activity impairment, y years
aP values were obtained using the Wilcoxon rank-sum test for numeric variables, and Fisher’s exact test for categorical variables
b Number of PsA symptoms currently present including joint symptoms tenderness, swelling, stiffness, etc.
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(28.9%), elevated cholesterol (20.0%), depression (14.1%), obe-
sity (13.8%), and anxiety (10.8%). Compared with that of the
aligned group, a greater percentage of patients in the misaligned
group had comorbidities (72.2 vs. 63.1%), including depression
(20.8 vs. 12.0%) and anxiety (15.3 vs. 9.4%) (Table 2).
In regard to work productivity, the misaligned group was sig-
nificantly more impaired by PsA in their overall work (mean %
[SD], 38.7 [27.9] vs. 21.4 [26.7], P = 0.0004), while at work
(mean % [SD], 36.2 [25.3] vs. 16.5 [21.2], P < 0.0001) and in
their daily activities (mean % [SD], 38.7 [24.5] vs. 22.3 [24.0],
P < 0.0001) compared with that of the aligned group. The
misaligned group had a significantly higher disease burden as
measured by HAQ-DI (mean [SD], 0.56 [0.43]) than that of the
aligned group (mean [SD], 0.37 [0.48]) (P = 0.0001) (Table 2).
Multivariate analysis: patient-physician misalignment
Satisfaction with PsA control in overall population
Multivariate analysis was performed to assess what characteris-
tics were associated with misalignment. After controlling for
baseline characteristics, the SJC and the HAQ-DI scores were
significantly associated with misalignment (Table 3, Model 1).
Multivariate analysis reported that with a higher SJC or HAQ-DI
score, the likelihood of being misaligned also increased. When
including only employed patients who completed the WPAI in
the multivariate analysis, no variables were found to be signifi-
cantly associated with misalignment (Table 3, Model 2).
Satisfaction with PsA control in patients with active disease
(>3 tender joint count)
To assess factors associated with satisfaction in PsA in pa-
tients who have active joint disease, we performed an
exploratory comparison of the characteristics of patients with
active joint disease (>3 TJC) who were satisfied or dissatisfied
with PsA control. A subset of 78 patients of the total popula-
tionwas identified from the database currently with active joint
disease. Overall, the majority of patients with active disease
were satisfied with their PsA control (Table 4). Compared with
dissatisfied patients with active joint disease, satisfied patients
tended to be older (mean [SD], 53.5 [12.3] vs. 44.3 [10.0] years
of age, P = 0.001, respectively), male (59.3% vs. 50.0%) had a
longer time since PsA diagnosis (mean year [SD], 6.5 [7.6] vs.
3.6 [3.9]), were more likely to be receiving bDMARD therapy
(64.8 vs. 56.5%), and had anxiety (13 vs. 33.3%, P = 0.06)
(Table 4). The level of PsA disease activity as measured by
SJC and TJC was similar between satisfied and unsatisfied
patients, although percentage of patients with >3%BSA affect-
ed by psoriatic lesions was lower in the satisfied patient group
(71.4 vs. 82.6%). The HAQ-DI score was also similar between
groups (mean [SD], 0.66 [0.50] vs. 0.76 [0.60]) (Table 4).
Discussion
Unlike prior studies, we surveyed a geographically diverse
sample of patients and physicians in a real-world clinical set-
ting in the USA. This analysis is also distinctive because it is
one of the first studies to assess the relationship between
patient-physician misalignment and PsA disease activity, de-
scribing detailed demographic and disease patient characteris-
tics in relation to the examined types of patients.
In this research, approximately 25% of physicians and their
PsA patients were misaligned with regard to their satisfaction
of PsA control, with the majority of misaligned cases
consisting of a satisfied patient and dissatisfied physician.
The misaligned group reported significantly more PsA
Table 3 Factors associated with
misalignment and subgroup
analysis of employed patients
with WPAI resultsa
Model 1b Model 2 (WPAI)
Variable OR (95% CI) P value OR (95% CI) P value
Age 1.00 (0.97–1.03) 0.857 1.00 (0.95–1.07) 0.753
Current bDMARD 0.83 (0.40–1.73) 0.621 0.54 (0.15–1.97) 0.347
SJC 1.13 (1.02–1.26) 0.020 1.16 (0.97–1.40) 0.103
BSA > 3% 0.62 (0.30–1.29) 0.205 0.81 (0.27–2.41) 0.701
HAQ-DI 2.51 (1.12–5.61) 0.025 3.44 (0.88–13.39) 0.074
WPAI 1.01 (0.99–1.03) 0.369
bDMARD biologic disease-modifying antirheumatic drug, BSA body surface area, CI confidence interval; HAQ-
DI health assessment questionnaire disability index, OR odds ratio, SJC swollen joint count, TJC tender joint
count, WPAI work productivity and activity impairment
a Number of observations was 196 and 92 for models 1 and 2, respectively. Continuous variables were patient age
(18 to 89 years), SJC (0 to 28), HAQ-DI (0 to 3), and WPAI (0 to 100). Categorical variables were current
bDMARD treatment (bDMARD/no bDMARD) and BSA (>3/≤3)
b TJC was excluded from the model due to the issue of multicollinearity with SJC
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symptoms, indicating increased PsA activity compared with
that of the aligned group. The percentage of patients with
comorbidities was also higher in the misaligned than that of
the aligned group. While some indicators of disease activity
were not significant, the number of differences and their
consistency leads the authors to believe that the misaligned
group had slightly more severe and active disease and were
generally more complex in presenting with more comorbidi-
ties. In addition, the majority of misalignment was due to
physician dissatisfaction with their patient’s PsA control.
Table 4 Baseline demographics and disease characteristics of PsA patients with active disease (>3 TJC)
Variable Overall, N = 78 Not satisfied, n = 24 Satisfied, n = 54 P valueb
Age (y), mean (SD) 50.6 (12.4) 44.3 (10.0) 53.5 (12.3) 0.001
Male, n (%) 44 (56.4) 12 (50.0) 32 (59.3) 0.469
Time since diagnosis (y), mean (SD) 5.6 (6.9) 3.6 (3.9) 6.5 (7.6) 0.174
Current bDMARD treatment, n (%) 0.609
None 29 (37.7) 10 (43.5) 19 (35.2)
Receiving bDMARD treatment 48 (62.3) 13 (56.5) 35 (64.8)
SJC, mean (SD) 5.1 (4.1) 5.0 (3.4) 5.1 (4.4) 0.681
TJC, mean (SD) 7.9 (4.5) 7.8 (3.4) 7.9 (4.9) 0.628
BSA affected, n (%) 0.340
≤3% 18 (25.0) 4 (17.4) 14 (28.6)
>3% 54 (75.0) 19 (82.6) 35 (71.4)
Number of PsA symptoms, mean (SD) 7.4 (3.7) 8.2 (3.4) 7.1 (3.8) 0.130
Number of PsA symptoms, n (%) 0.195
≤5 25 (32.1) 5 (20.8) 20 (37.0)
>5 53 (67.9) 19 (79.2) 34 (63.0)
Comorbidities
Number of comorbidities per patient,
mean (SD)
1.8 (1.6) 2.2 (1.8) 1.6 (1.5) 0.130
Frequency of comorbidities (≥1),
n (%)
61 (78.2) 20 (83.3) 41 (75.9) 0.562
Comorbidities, n (%)
Hypertension 24 (30.8) 9 (37.5) 15 (27.8) 0.432
Obesity 20 (25.6) 5 (20.8) 15 (27.8) 0.586
Depression 18 (23.1) 8 (33.3) 10 (18.5) 0.243
Hyperlipidemia 17 (21.8) 7 (29.2) 10 (18.5) 0.374
Type 2 diabetes 16 (20.5) 3 (12.5) 13 (24.1) 0.364
Anxiety 15 (19.2) 8 (33.3) 7 (13.0) 0.06
Gastric condition 14 (17.9) 6 (25.0) 8 (14.8) 0.342
Respiratory condition 5 (6.4) 3 (12.5) 2 (3.7) 0.166
Malignancy 4 (5.1) 1 (4.2) 3 (5.6) >0.999
Renal impairment 3 (3.8) 2 (8.3) 1 (1.9) 0.223
Liver impairment 2 (2.6) 1 (4.2) 1 (1.9) 0.524
WPAI due to PsA, mean (SD)a
Percentage of work-time missed 12.6 (21.0) 8.1 (9.1) 14.0 (23.5) 0.738
Percentage of impairment while working 32.7 (24.0) 32.9 (23.3) 32.6 (24.6) 0.921
Overall percentage of work impairment 39.9 (28.1) 40.5 (23.8) 39.7 (29.6) 0.710
Percentage of activity impairment 41.4 (22.1) 47.9 (21.3) 38.5 (22.0) 0.114
HAQ-DI, mean (SD) 0.69 (0.53) 0.76 (0.60) 0.66 (0.50) 0.410
bDMARD biologic disease-modifying antirheumatic drugs, BSA body surface area, HAQ-DI health assessment questionnaire disability index, PsA
psoriatic arthritis, SD standard deviation, SJC swollen joint count, TJC tender joint count, WPAI work productivity and activity impairment; y years
aWPAI was not available for all patients evaluated. Thirty-eight employed patients provided overall WPAI scores; nine from the not satisfied group and
29 from the satisfied group
b P values were obtained using the Wilcoxon rank-sum test for numeric variables, and Fisher’s exact test for categorical variables
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This misalignment may be an indicator that the treatment
goals may or may not have been aligned between physicians
and patients (i.e., reduced disease activity vs. remission).
Multivariate analysis found that a greater SJC and a higher
HAQ-DI score were significantly associated with patient-
physician misalignment. However, in the patient-physician
group in which patients were employed and had completed
the WPAI, there were no variables significantly associated
with misalignment. The lack of significance may be due to
the smaller number of employed patients and within this de-
creased sample size, only 38 patients had available WPAI
information. The findings from this exploratory analysis sug-
gest that misalignment may be associated with more active
disease and poorer PsA control, increased comorbidities, more
extensive disability, and unemployment. Nevertheless, the
majority of patients with active disease were satisfied with
their PsA control.
Our findings are consistent with prior smaller single-center
studies that assessed factors that may influence the differences
in patient-physician alignment with regard to PsA activity and
control [11, 18, 19]. Previous studies found that patients with
PsA experience a more severe burden of disease than that
perceived by the physician [11, 18], and nearly one quarter
to a third of patients with PsA were misaligned with their
physicians [11]. The earlier studies found greater misalign-
ment regarding the perception of disease activity in the joints
than that of the skin symptoms (i.e., TJC, SJC vs. psoriasis,
etc.) [11, 18, 19], possibly indicating that skin lesions are more
obvious and easily perceived, so are easier to Balign^ [19]. In
previous PsA studies, factors associated with misalignment
were SJC, TJC, pain, and fatigue [11, 18, 19]. Increased TJC
and SJC resulted in worse physician assessment of arthritis
[11]. A meta-analysis found that the number of swollen and
tender joints influenced the perception of disease activity.
Patient-reported and trained observer assessment for SJC
showed lower levels of correlation than those of patient-
reported TJC [24].
In one study, pain and fatigue were the two major causes for
misalignment and resulted in worse patient assessment of their
disease [11]. We did not assess the association between pain and
fatigue with patient and physician misalignment in this study. In
previous PsA studies, misalignment was predominately in pa-
tients with worse self-rating of overall disease activity [11, 18].
Differences in ratings of disease activity between physicians and
patients may be influenced by a number of factors such as lower
education level, being a smoker, being unemployed, and
experiencing depression, anxiety, and fibromyalgia [11]. This
study analyzed some of these associations in a bivariate manner;
however, we did not analyze these associations with misalign-
ment in themultivariatemodel due to the relatively small number
of misaligned completed surveys and validity concerns.
Satisfaction is seen as an indicator of quality of health care
[25, 26]. In our study, about 69% of patient with active disease
were still satisfied with control of their PsA. Though specula-
tive in nature, these findings suggest that patients with active
disease may Bsettle^ for suboptimal control of joint activity
based on their previous experience, particularly in patients
with longer disease duration and bDMARD use [27]. A recent
study reported higher treatment satisfaction among patients
than that of physicians and noted that patients may assess
disease severity differently from physicians by considering
symptoms that may not be captured during a physician visit
[28]. Other factors found to influence satisfaction with care in
patients with PsA include involvement in healthcare decision-
making, and access to health care services, particularly rheu-
matology services, and adequacy of health care facilities [20,
29, 30]. These factors were not available for analysis in our
data.
The challenges in evaluating disease activity have been
described in numerous survey-based RA studies, where mis-
alignment between patient and physician global disease as-
sessment was reported in approximately 30% of patients with
RA [31–34]. Alignment between patient and physician satis-
faction of disease control improves the chances of a treatment
plan being successfully implemented [13]. A patient-centered
approach in managing chronic illnesses, where patients par-
ticipate and share activity in treatment and management of the
disease that takes into account individual preference with so-
cial context [4], helps to promote the alignment of the patient
and physician on treatment and disease management [13].
Patients involved in decision-making appear to have better
outcomes and are more likely to be satisfied with their health
care [29, 30]. The treat-to-target approach asks the practitioner
to treat towards the goal of remission or minimal disease ac-
tivity [14, 16]. The current study finds that, in some cases,
even though some patients had some disease activity (i.e.,
increased swollen joint counts), they were still satisfied. In
other instances, patients were satisfied with their PsA control,
whereas the physician was not. This idea of misalignment in
disease control may add important information for decisions
made by physicians using the currently recommended treat-to-
target approach for managing PsA [16]. It also encourages
both the patient and physician to align on a similar treatment
goal.
There are several limitations to this analysis. The sample
collected in the Disease Specific Programme is not a truly
random sample of patients. Patients included in the Disease
Specific Programme sample were the next three patients with
PsA who consulted the physician. While a reasonable ap-
proach, it may not truly represent the overall population of
patients with PsA, as patients who consult frequently are more
likely to be included in the sample. However, the patients are
representative of the patient population who consult rheuma-
tologists. This study used the 28 TJC which may have been
less specific for PsA than the 66 SJC and the 68 TJC.We only
included SJC and did not include TJC in our multivariate
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analysis, specifically because we wished to include patients
most likely to have true inflammatory disease. The methodol-
ogy used in the Disease Specific Programme has some limi-
tations that are common to all survey-based methodologies
including potential recall bias, possible physician selection
bias (the survey focused on rheumatologists who saw at least
a minimum number of PsA patients), physician willingness to
fill out a survey themselves, and potential biases engendered
by the specific questionnaires used which may not reflect all
aspects of individual impairment from the patient’s point of
view [18]. In common with any research where participation
is voluntary including clinical trials, inclusion of patients and
physicians may also be subject to bias.
Future research should include a large sample of PsA patients
and paired-provided survey responses to further investigate the
reasons for dissatisfaction and satisfaction among patients and
providers. Among the misaligned patients and providers, a com-
parison should be conducted to separately examine the satisfied
patients and dissatisfied providers and vice versa.
Conclusion
In conclusion, our findings in a diverse PsA population indi-
cate that about a quarter of patients with PsA are misaligned
with their rheumatologists in their satisfaction with their PsA
control. Patient-physician misalignment is associated with in-
creased disease activity and disability among patients with
PsA. Our findings stress the importance of strong and effec-
tive communication between patients and their physicians in
treating this chronic disease.
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